Superworth

ImageneBio revenue IMA

Sales by quarter and over the last twelve months, from 2020.

Last 12 months, to Dec 31, 2025
$800K
Latest quarter, Q4 FY25
$0
Fiscal year 2025
$800K

ImageneBio's revenue was $800K over the twelve months to Dec 31, 2025.

In its latest quarter, Q4 FY25, it was $0.

Over the five fiscal years to FY2025 it shrank 39% a year on average.

Revenue over time

Open the interactive chart, with overlays and comparisons

Fiscal year by fiscal year

Fiscal yearRevenueChange
FY2025$800Kn/a
FY2024n/an/a
FY2023$9.2M−41%
FY2022$15.6M−50%
FY2021$31M+237%
FY2020$9.2Mn/a

Each fiscal year is the twelve months to its fourth quarter.

Quarter by quarter

QuarterEndedRevenueOn a year earlierLast 12 months
Q4 FY25$0n/a$800K
Q3 FY25$0−100%$800K
Q2 FY25$0n/a$4.3M
Q1 FY25$800Kn/an/a
Q4 FY24$0−100%n/a
Q3 FY24$3.5M+195%n/a
Q4 FY23$659K−88%$9.2M
Q3 FY23$1.2M−81%$14M
Q2 FY23$2M+425%$19.2M
Q1 FY23$5.3M+57%$17.5M
Q4 FY22$5.5M−73%$15.6M
Q3 FY22$6.4M+71%$30.4M

Against its peers

Companies in Healthcare nearest ImageneBio's size, closest first, today.

CompanyRevenue, 12 monthsGrowth
IMAImageneBion/m
ATNMActinium Pharmaceuticalsn/m
APTAlpha Pro Tech$61.9M+6% a year
NEPHNephros$20.7M+24% a year
SPROSpero Therapeutics$47M−3% a year
LFVNLifevantage$182.6M−20% a year
ICCCImmucell$30.7M+8% a year
KEQUKewaunee Scientific$277.2M+5% a year
PDEXPro DEX$77.5M+16% a year
PLXProtalix BioTherapeutics$80.6M+30% a year
NATRNatures Sunshine Products$492M+7% a year
Peer median$77.5M

What the revenue tells you

Total sales in the period. On the company page, quarterly bars or the trailing twelve months (TTM), which smooths seasonality.

Growing revenue with shrinking margins is a warning, not a win.

More on ImageneBio

Valuation data, not investment advice. Prices as of . Reported figures come from the company's filings with the SEC.